Also, different nanobodies were developed against tumor molecules; some of them target the growth factor receptors such as the epidermal growth factor receptor 1, 2 (EGFR-1, 2) (25), vascular endothelial growth factor receptor-2 (VEGFR-2)(26), human epidermal growth factor receptor-2 (HER-2) (27), mesenchymal-epithelial transition factor (c-Met) (28) and chemokine receptor (29), and others target the growth factors such as hepatocyte growth factor (HGF) (30) and vascular endothelial growth factor (VEGF) (31). This evidence concerns the gene ERBB2 and neoplasm.